NO20083497L - Modulering av bendannelse - Google Patents

Modulering av bendannelse

Info

Publication number
NO20083497L
NO20083497L NO20083497A NO20083497A NO20083497L NO 20083497 L NO20083497 L NO 20083497L NO 20083497 A NO20083497 A NO 20083497A NO 20083497 A NO20083497 A NO 20083497A NO 20083497 L NO20083497 L NO 20083497L
Authority
NO
Norway
Prior art keywords
ror2
modulation
bone formation
bone
activity
Prior art date
Application number
NO20083497A
Other languages
English (en)
Norwegian (no)
Inventor
Julia Billiard
Yan Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20083497L publication Critical patent/NO20083497L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20083497A 2006-02-17 2008-08-13 Modulering av bendannelse NO20083497L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13
PCT/US2007/004510 WO2007098198A2 (en) 2006-02-17 2007-02-16 Modulation of bone formation

Publications (1)

Publication Number Publication Date
NO20083497L true NO20083497L (no) 2008-10-31

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083497A NO20083497L (no) 2006-02-17 2008-08-13 Modulering av bendannelse

Country Status (19)

Country Link
US (1) US20090047287A1 (es)
EP (1) EP1984395A2 (es)
JP (1) JP2009527485A (es)
KR (1) KR20080095269A (es)
AR (1) AR060104A1 (es)
AU (1) AU2007217779A1 (es)
BR (1) BRPI0707864A2 (es)
CA (1) CA2638803A1 (es)
CR (1) CR10212A (es)
EC (1) ECSP088682A (es)
IL (1) IL193271A0 (es)
MX (1) MX2008010511A (es)
NO (1) NO20083497L (es)
PA (1) PA8715601A1 (es)
PE (1) PE20071309A1 (es)
RU (1) RU2008131052A (es)
SV (1) SV2009002997A (es)
TW (1) TW200800266A (es)
WO (1) WO2007098198A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566886A1 (en) * 2010-05-05 2013-03-13 Addex Pharma SA Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
EP2800975A4 (en) * 2012-01-03 2015-12-09 Univ Leland Stanford Junior ANALYSIS AND TARGETING OF ROR2 IN CANCER
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び/または品質評価を行う方法
JP6850944B2 (ja) * 2014-08-01 2021-04-14 PuREC株式会社 ヒト間葉系幹細胞の品質評価方法、ヒト間葉系幹細胞の分離、選別及び培養方法並びに増殖の早いヒト間葉系幹細胞の細胞集団
WO2017022628A1 (ja) * 2015-07-31 2017-02-09 国立大学法人大阪大学 上皮疾患に対する治療及び/又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
AU2017263568B2 (en) 2016-05-13 2024-01-18 Bioatla, Llc Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
AU2001238571A1 (en) * 2000-03-14 2001-09-24 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
EP1603586A1 (en) * 2003-02-19 2005-12-14 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
AU2004233060A1 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity

Also Published As

Publication number Publication date
US20090047287A1 (en) 2009-02-19
PA8715601A1 (es) 2008-11-19
TW200800266A (en) 2008-01-01
CR10212A (es) 2008-10-03
ECSP088682A (es) 2008-09-29
KR20080095269A (ko) 2008-10-28
RU2008131052A (ru) 2010-03-27
SV2009002997A (es) 2009-04-17
AR060104A1 (es) 2008-05-28
JP2009527485A (ja) 2009-07-30
AU2007217779A1 (en) 2007-08-30
EP1984395A2 (en) 2008-10-29
IL193271A0 (en) 2011-08-01
PE20071309A1 (es) 2008-02-13
CA2638803A1 (en) 2007-08-30
WO2007098198A3 (en) 2008-03-13
WO2007098198A2 (en) 2007-08-30
MX2008010511A (es) 2008-11-18
BRPI0707864A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
NO20083497L (no) Modulering av bendannelse
EP2336174B8 (en) Human monoclonal antibodies against Hendra and Nipah viruses
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
NO20060235L (no) Sammensetninger og fremgangsmater for a oke benmineralisering
CY1118977T1 (el) Επιτοποι σκληροστινης
NO20083268L (no) Antistoffer anvist til HER-3 og anvendelser derav
GT201200271A (es) Proteínas que se unen al tnf-a
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
NO20083793L (no) Antistoffer mot amyloid-beta peptid
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
WO2007100465A3 (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
NO20084878L (no) Humanisert C-kit antistoff
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
GB0514779D0 (en) Biological products
ATE526585T1 (de) Natürlicher ligand des g-protein-gekoppelten rezeptors rcc356 und verwendungen davon
NO20080609L (no) Systemer og fremgangsmater for separering av proteiner fra bindevev
WO2018115017A3 (en) CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR
MX2010001237A (es) Nuevos anticuerpos.
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
AR071885A1 (es) Proteinas de union al receptor de interleuquina 21

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application